Abstract
Heart failure (HF) is a leading cause of death worldwide, and effective treatments for HF are lacking. Infusion of the growth factor neuregulin-1 (NRG-1) is a promising therapy currently undergoing clinical trials for HF. NRG-1 activates growth factor receptors on cardiomyocytes (predominantly ErbB4, but also ErbB3) to confer protection. Clinically, NRG-1 infusion therapy is limited because it is dose-limited by liver damage and systemic delivery of a potent growth factor has the capacity to promote oncogenesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
